*Disseminated on Behalf of VolitionRx Ltd. Please see disclosures below.
|
|
|
Reasons to Keep an Eye on VolitionRX (VNRX)
|
|
|
|
|
|
Hey Folks,
Here are some key reasons why VolitionRX (VNRX) is worth taking a look at...
1. Commercial Veterinary Validation: The Nu.Q Vet Cancer Test is already available across the United States, Europe, Australia, and parts of Asia, with over 120,000 tests and components sold in 2024. Cancer is the leading cause of death in dogs over age two, giving the test a clear, sustained use case in the veterinary market.
2. Tier-1 Distribution Partners: Volition's veterinary product reaches the market through Antech and IDEXX — the two dominant players in animal diagnostics.
3. $23M Already Paid by Antech: The exclusive licensing agreement with Antech has generated $10 million upfront plus $13 million in milestone payments to date — meaningful non-dilutive capital for a development-stage company, with additional milestones still ahead.
4. Capture-Seq Hits 99%+ Purity: In March, Volition reported a breakthrough achievement of over 99% purity in isolating circulating tumor DNA from plasma. Purity is one of the central technical hurdles in liquid biopsy, and clearing that bar puts Capture-Seq in serious territory.
5. Strong Early-Stage Sensitivity: A blinded validation cohort of 81 subjects — including colorectal and lung cancer patients alongside healthy controls — achieved over 95% sensitivity for Stage I and Stage II cancers at 95% specificity.
6. CE-Marked Sepsis Test: The Nu.Q NETs test has received CE marking for use in Europe and addresses a condition that claims an estimated 11 million lives annually. Current sepsis diagnostics are slow and imprecise, leaving a wide opening for a faster blood-based approach.
Anyways...
That's all for now!
Until Next Time,
-ZT Team
|
P.S. Want our text alerts?
Text “ZIPTRADER” to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply)
|
|
|
|
*Disseminated on Behalf of VolitionRx Ltd. Please see disclosures below.
|
|
|
|
|
5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA
|
|
This email was sent to punjabsvera@gmail.com
|
|
*SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via YouTube, email, and SMS on behalf of VolitionRx Ltd (VNRX) from April 28, 2026 to April 29, 2026. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via YouTube, email, and SMS on behalf of VolitionRx Ltd (VNRX) from March 17, 2026 to March 18, 2026. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via YouTube, email, and SMS on behalf of VolitionRx Ltd (VNRX) from February 24, 2026 to February 25, 2026. ZipTrader has been compensated fifteen thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via email and SMS on behalf of VolitionRx Ltd (VNRX) from January 19, 2026 to January 20, 2026. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via YouTube, email, and SMS on behalf of VolitionRx Ltd (VNRX) from December 16, 2025 to December 17, 2025. ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for VolitionRx Ltd (VNRX). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in VolitionRx Ltd (VNRX). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of VolitionRx Ltd (VNRX), increased trading volume, and possibly an increased share price of VolitionRx Ltd (VNRX), which may or may not be temporary and decrease once the marketing arrangement has ended.
|
|
BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service. See Our Advertisement Disclaimer.
|
|
|
|
|
|
|
|
|
